[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Naso et al., 2024 - Google Patents

The α-Gal KO Mouse Animal Model is a Reliable and Predictive Tool for the Immune-Mediated Calcification Assessment of Heart Valve Bioprostheses

Naso et al., 2024

View HTML
Document ID
1943542103939978375
Author
Naso F
Gandaglia A
Sturaro G
Galli C
Melder R
Publication year
Publication venue
Frontiers in Bioscience-Landmark

External Links

Snippet

Background: Recent studies highlighted the presence of anti-α-Gal antibodies in patients implanted with commercial bioprosthetic heart valves (BHVs). BHVs expose residual α-Gal xenoantigen and their recognition by the circulating anti-Gal antibodies leads to …
Continue reading at www.imrpress.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates

Similar Documents

Publication Publication Date Title
Naso et al. Alpha‐Gal detectors in xenotransplantation research: a word of caution
Naso et al. Different approaches to heart valve decellularization: A comprehensive overview of the past 30 years
CN103491986B (en) The method of enzymatically treating of tissue products
Bloch et al. Immune response in patients receiving a bioprosthetic heart valve: lack of response with decellularized valves
Connor et al. Retention of structural and biochemical integrity in a biological mesh supports tissue remodeling in a primate abdominal wall model
McGregor et al. Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves
JP5916615B2 (en) A method for obtaining a bioprosthesis for implantation in a body with reduced mineralization.
JP2004267791A5 (en)
Lee et al. Human antibody recognition of xenogeneic antigens (NeuGc and Gal) on porcine heart valves: could genetically modified pig heart valves reduce structural valve deterioration?
US20190231931A1 (en) Methods of removing alpha-galactose
JP2013526889A5 (en)
Lim et al. In vivo efficacy of alpha-galactosidase as possible promise for prolonged durability of bioprosthetic heart valve using alpha1, 3-galactosyltransferase knockout mouse
Ground et al. Models of immunogenicity in preclinical assessment of tissue engineered heart valves
Kim et al. Differences in xenoreactive immune response and patterns of calcification of porcine and bovine tissues in α-Gal knock-out and wild-type mouse implantation models
Calafiore et al. Immunoreaction to xenogenic tissue in cardiac surgery: alpha-Gal and beyond
Naso et al. The α-Gal KO Mouse Animal Model is a Reliable and Predictive Tool for the Immune-Mediated Calcification Assessment of Heart Valve Bioprostheses
ES2881603T3 (en) Method to inactivate xenoantigens in biological tissues
Naso et al. The α-Gal KO Mouse Animal Model is for the Immune-Mediated Calcification Assessment of Heart Valve Bioprostheses
Naso et al. Correlations between the alpha-gal antigen, antibody response and calcification of cardiac valve bioprostheses: experimental evidence obtained using an alpha-gal knockout mouse animal model
Chong et al. Anti-galactose-α (1, 3) galactose antibody production in α1, 3-galactosyltransferase gene knockout mice after xeno and allo transplantation
Naso et al. In-vivo subdermal implant in the alpha-Gal knockout mice model for the assessment of bioprosthetic heart valve calcification rate before and after a polyphenols-based treatment
Kyriakopoulou Quantitative analysis of α-Gal trisaccharide content and its contribution to degeneration of bioprosthetic heart valves
WO2023076897A1 (en) Viable galactosyltransferase knock-out sheep and related methods
Lee et al. Jeong2, Won Ryang Wee1, 2 1Seoul National University Hospital, Department of Ophthalmology; 2Seoul Na-tional University Hospital Clinical Research Institute, Laboratory of Corneal Re-generative Medicine and Ocular Immunology, Seoul Artificial Eye Center; Seoul